Can Adagrasib be reimbursed by medical insurance?

Adagrasib (Adagrasib) is a KRAS G12C inhibitor, mainly used to treat patients with non-small cell lung cancer carrying KRAS G12C mutations. As a new targeted drug, adagrasib has received widespread attention internationally and has been approved by the FDA in the United States. However, this drug has not yet been officially approved for marketing in mainland China, so it cannot be found in the domestic medical insurance directory. If patients need medicines, they can only obtain them through overseas channels.

Since it is not yet on the market in China, adagrasib cannot be reimbursed through medical insurance, and all costs must be borne by the patient. This is undoubtedly a heavy burden for ordinary families. The price of original research drugs in the United States is extremely high, with the price per box reaching more than 100,000 yuan. Long-term use of the drugs will create huge economic pressure. And even if patients are willing to bear high costs, the purchase process is relatively complicated and needs to be completed through overseas medical services or purchasing agents.

In order to solve the problem of high costs, some patients choose to purchase relatively low-priced Laotian generic drugs. This type of generic version is basically the same as the original drug in terms of drug ingredients and treatment mechanism, and has similar efficacy, but the price is only more than 3,000 yuan per box, which greatly alleviates the financial pressure on patients. However, generic drugs have not been approved by the Chinese Food and Drug Administration and must be used with caution and under the guidance of professional doctors to ensure safety and efficacy.

Generally speaking, adagrasib does not yet meet the conditions for reimbursement in China. If patients really need the drug, they need to obtain it through foreign channels and comprehensively evaluate various factors such as drug source, price, and use risks. While waiting for the drug to officially enter the Chinese market, patients are advised to communicate with their doctors regularly to evaluate suitable alternative treatment options to ensure the continuity and effectiveness of treatment.

References：https://www.krazati.com/